Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection

NCT02738333 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

239

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: LDV/SOF
DRUG: SOF
DRUG: RBV

Sponsor

Gilead Sciences